Joseph Rotino | Vice President, Quality Assurance And Regulatory Affairs
Cryoport Inc

Joseph Rotino, Vice President, Quality Assurance And Regulatory Affairs, Cryoport Inc

Joseph Rotino has extensive background in setting quality, regulatory and compliance standards and systems in the medical device industry. Before joining Cryoport, Mr. Rotino was Vice President of Quality and Regulatory Affairs at Biolase, Inc., which designs and manufactures dental laser systems. There, he led efforts in quality systems development, supplier quality improvements, operational and product development enhancements, with oversight of all quality, regulatory and clinical compliance.

Prior to that, he served as Director of Quality Assurance for Johnson & Johnson’s Advanced Sterilization Products division, leading quality efforts in both new product development and life-cycle management, as well as lead role in the Terminal Sterilization Strategic Business Unit. Prior to J&J, Rotino served as Vice President of Quality and Regulatory for Pro-Dex, Inc. which developed and manufactured powered surgical devices, and Vice President of Quality Assurance for Sybron Dental Specialties (a Danaher Company), a leader in orthodontic, endodontic, dental composites and implants.

Early in his career, Rotino held leadership positions at Baxter Healthcare, Kendall McGaw (currently B. Braun), and ITT corporations, were he established key quality systems and developed expertise in numerous manufacturing processes.

Rotino holds both a MS in Quality Assurance, and BS in Mathematics.


15th May Pre-Conference Workshops and Summits Day @ 13:00

Panel discussion: Regenerative medicine globalization; considerations for effective launch activity beyond your initial geographic launch

15th May Pre-Conference Workshops and Summits Day @ 15:00

Scalability (Series of 30 min panel discussion sessions)

Conference Day 1: Thursday 16th May 2019 @ 17:00

Quality systems for regenerative medicine delivery: basic quality requirement for distribution

  • Current and future required quality systems standards for the regenerative medicine industry
  • A comprehensive review of the basic quality systems requirements
  • Regulatory considerations critical in the successful launch and management of the risks in distribution
last published: 18/Mar/19 11:45 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.


Erica Baeta 
+44 (0)207 092 1152


Jessica Robinson 
t/ +44 (0)207 092 1150


Issa Mauthoor 
+44 (0)207 092 1257